Curis (CRIS) swings to Q4 profit but warns of funding shortfall
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Curis, Inc. reported a sharply improved 2025 bottom line, with full-year net loss narrowing to $7.6 million ($0.58 per share) from $43.4 million in 2024, and fourth-quarter 2025 net income of $19.4 million versus a prior-year loss of $9.6 million. Results were driven largely by a non-cash $27.2 million gain from extinguishing the liability tied to the sale of future Erivedge royalties, after Curis sold its Erivedge-related interests and is no longer entitled to royalty revenues. Research and development and general and administrative expenses both declined year over year. As of December 31, 2025, cash and cash equivalents were $5.1 million with about 12.9 million shares outstanding. A January 2026 PIPE financing provides up to $80.8 million in potential gross proceeds, and Curis estimates its cash, including $20.2 million already received and up to $20.2 million from potential Series B warrant exercises, should fund operations into the second half of 2027. The company also notes it does not have sufficient cash on hand to support current operations for 12 months from the press release date and will require substantial additional capital to advance emavusertib.
Positive
- Sharp improvement in reported earnings: 2025 net loss narrowed to $7.6 million from $43.4 million, and Q4 2025 delivered net income of $19.4 million versus a prior-year loss, aided by a $27.2 million gain extinguishing the royalty liability.
- Expense reductions and potential funding runway: Research and development and general and administrative costs declined year over year, and a January 2026 PIPE financing for up to $80.8 million underpins guidance that available cash and warrant proceeds could fund operations into the second half of 2027.
Negative
- Loss of royalty revenue stream: Curis sold its Erivedge-related interests and recognized a non-cash $27.2 million gain, but it is no longer entitled to royalty revenues under the License Agreement, reducing recurring revenue going forward.
- Significant going-concern style funding risk: The company explicitly states that, based on available cash resources, it does not have sufficient cash on hand to support current operations within 12 months from the press release date and will require substantial additional capital to continue developing emavusertib and fund operations.
Insights
Improved 2025 results rely on one-time royalty gain amid funding risk.
Curis posted full-year 2025 net loss of $7.6 million, far better than 2024’s $43.4 million, and fourth-quarter net income of $19.4 million versus a loss a year earlier. This swing is mainly from a non-cash $27.2 million gain extinguishing its royalty liability after selling Erivedge-related rights.
Operating trends were more modest: revenues slipped to $9.4 million, while research and development and general and administrative expenses declined, reflecting cost controls. However, selling the Erivedge royalty stream removes a recurring revenue source, increasing dependence on financing and future success of emavusertib in lymphoma, CLL and AML.
Liquidity is a key concern. Cash was only $5.1 million at year-end 2025. A January 2026 PIPE could bring up to $80.8 million, and management believes existing cash plus PIPE proceeds may fund operations into the second half of 2027. Yet the company states it lacks sufficient cash to support operations for 12 months from this press release and will require substantial additional capital, highlighting ongoing financing and execution risk.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): March 19, 2026
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||
| (Address of Principal Executive Offices) (Zip Code) | ||
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | ||||||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 19, 2026, Curis, Inc. announced its financial results for the three- and twelve-month periods ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
| Exhibit Number | Description | |||||||
| 99.1 | Press Release dated March 19, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the InLine XBRL document) | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Curis, Inc. | |||||||||||
| Date: | March 19, 2026 | By: | /S/ JAMES E. DENTZER | ||||||||
| James E. Dentzer | |||||||||||
| President and Chief Executive Officer | |||||||||||
Exhibit 99.1
PRESS RELEASE
Curis Provides Fourth Quarter 2025 Business Update
Management to host conference call today at 4:30 p.m. ET
LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2025.
Operational Highlights
TakeAim Lymphoma
•Lakshmi Nayak, MD, Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute in Boston, presented a poster with updated clinical data in Primary CNS Lymphoma (PCNSL) at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) in November 2025. The poster, titled Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients, showed results for 24 patients who have received treatment with emavusertib and ibrutinib, a BTK inhibitor (BTKi), for at least 1 cycle (28 days):
◦5 of 5 BTKi-naïve patients achieved objective response (100% ORR)
◦7 of 19 BTKi-experienced patients achieved objective response (37% ORR)
◦Median treatment duration for the 12 responders was 123 days (44 – 798 days)
◦9 additional patients were unable to complete 1 cycle of treatment; reasons for discontinuing treatment included adverse events unrelated to treatment, disease progression, and transition to hospice care.
•Cecilia Merrigan, DNP, Mayo Clinic in Rochester, presented a poster with initial clinical data in Secondary CNS Lymphoma (SCNSL) at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) in November 2025. The poster, titled Promising Efficacy Signal in Secondary CNS Lymphoma Patients Treated with Emavusertib and Ibrutinib, showed results for 2 patients who had previously progressed on a BTKi. Adding emavusertib to their ibrutinib treatment resulted in 1 complete response (CR) and 1 stable disease (SD) with a 38% reduction in disease burden.
•Curis continues to enroll PCNSL patients in the Company’s TakeAim Lymphoma study of emavusertib in combination with ibrutinib which, as a result of discussions with FDA and EMA, is intended to support filings for accelerated approval in PCNSL in the US and Europe. Emavusertib has been granted orphan drug designation by both FDA and EMA in PCNSL.
TakeAim CLL
•Curis initiated an open label Phase 2 clinical study of emavusertib in combination with zanubrutinib, a BTKi, in patients with Chronic Lymphocytic Leukemia (CLL). The goal of combining emavusertib with a BTKi is to enable a dual blockade of NF-kB, a key driver of disease
in CLL and NHL, by inhibiting both the TLR and BCR pathways. The current standard of care is BTKi, which blocks the BCR pathway and can deliver high response rates, though typically only partial responses. Previous clinical studies have shown that adding emavusertib, which blocks the TLR pathway, to a BTKi regimen can enable patients with NHL to achieve deeper responses, including complete remission or undetectable minimal residual disease (MRD) and the potential for time-limited treatment, outcomes which represent the potential for a paradigm shift in the management of CLL.
AML
•Christina Papayannidis, MD, IRCCS Azienda Ospedaliero Universitaria di Bologna, presented a poster with initial clinical data in frontline AML at the 67th ASH Annual Meeting in December. The AML triplet study (CA-4948-104) is evaluating the addition of emavusertib to the combination of azacitidine and venetoclax (aza-ven) in AML patients who have achieved complete remission on aza-ven but remain MRD-positive (MRD+). The first two cohorts in the study evaluate patients who received emavusertib for either 7 or 14 days in a 28-day cycle, in addition to their aza-ven treatment. The poster, titled Preliminary Pharmacokinetic and MRD Results from AML Patients Treated with 7- and 14-Day Dosing Schedule of Emavusertib added to Combination Therapy with Azacitidine and Venetoclax, showed results for 4 patients in the 7-day cohort and 6 patients in the 14-day cohort:
◦8 patients had central MRD samples
◦5 of 8 patients (62.5%) achieved MRD conversion (MRD+ to undetectable).
Corporate
On January 9, 2026, the Company announced the closing of a private placement (the "January 2026 PIPE Financing") with gross proceeds of up to $80.8 million, including initial gross proceeds of approximately $20.2 million with three series of warrants (A, B, and C) which can be exercised for up to $20.2 million each according to the terms and conditions of the financing agreement. All three series of warrants are currently exercisable at $0.75 per share and have the following termination conditions:
•Series A warrants terminate on January 8, 2031
•Series B warrants terminate 30 days after the Company announces dosing of the fifth patient in the Phase 2 clinical trial in CLL, subject to conditions defined in the financing agreement
•Series C warrants terminate on January 8, 2027.
Fourth Quarter 2025 Financial Results
For the year ended December 31, 2025, Curis reported a net loss of $7.6 million, or $0.58 per share on both a basic and diluted basis, as compared to a net loss of $43.4 million, or $6.88 per share on both a basic and diluted basis in 2024. For the fourth quarter of 2025, Curis reported net income of $19.4 million or $1.23 per share on both a basic and diluted basis as compared to a net loss of $9.6 million or $1.25 on both a basic and diluted basis for the same period in 2024.
Revenues, net were $9.4 million and $10.9 million for the years ended December 31, 2025 and 2024, respectively. Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge®. Revenues were $1.1 million and $3.3 million for the fourth quarters of 2025 and 2024, respectively. As previously announced, on November 6, 2025, the Company sold to TPC Investments Royalty LLC, a limited liability company managed by Oberland, its interest in Curis Royalty LLC. The sale included the Erivedge intellectual property, other assets associated with Erivedge and the License Agreement with Genentech (“Erivedge”), in exchange for upfront consideration of $2.5 million and a release of the Company’s liability related to sale of future royalties to Oberland. In connection with such transaction, the Company transferred to Curis Royalty all rights to Curis Technology, Inventions and Joint Patents (each as defined in the License Agreement) and assigned the Company’s rights, duties and
obligations under the License Agreement to Curis Royalty. Following the sale, the Company is no longer entitled to revenues under the License Agreement.
Research and development expenses were $28.3 million and $38.6 million for the years ended December 31, 2025 and 2024, respectively. The decrease was primarily attributable to lower employee-related, clinical, manufacturing and consulting costs. Research and development expenses were $5.8 million and $9.0 million for the fourth quarters of 2025 and 2024, respectively.
General and administrative expenses were $14.0 million and $16.8 million for the years ended December 31, 2025 and 2024, respectively. The decrease was primarily attributable to lower employee-related and legal costs. General and administrative expenses were $2.9 million and $3.4 million for the fourth quarters of 2025 and 2024, respectively.
Gain on release of liability related to sale of future royalties associated with sale of assets was the result of the sale of Erivedge. In the fourth quarter 2025, the Company recognized a non-cash $27.2 million gain and the liability related to sale of future royalties was extinguished.
Other expense, net was $1.9 million for the year ended December 31, 2025 and other income, net was $1.2 million for the year ended December 31, 2024. The increase was partially attributable to an increase in expense related to the sale of future royalties and a decrease in interest income. Other expense, net was $0.3 million and $0.6 million for the fourth quarters of 2025 and 2024, respectively.
As of December 31, 2025, Curis's cash and cash equivalents totaled $5.1 million, and the Company had approximately 12.9 million shares of common stock outstanding.
Cash Runway Guidance
Curis believes its cash and cash equivalents as of December 31, 2025, together with initial gross proceeds of $20.2 million received in January 2026 and expected gross proceeds of up to an additional $20.2 million from the exercise of the January 2026 PIPE Financing Series B Warrants upon the public announcement of dosing the 5th CLL patient in our TakeAim CLL study expected later this year, should enable the Company’s planned operations into the second half of 2027.
Conference Call Information
Curis management will host a conference call today, March 19, 2026, at 4:30 p.m. ET, to discuss the business update and these financial results.
To access the live conference call, please dial (800)-836-8184 from the United States or (646)-357-8785 from other locations, shortly before 4:30 p.m. ET. The conference call can also be accessed here on the Curis website in the Investors section.
About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL). The Company’s monotherapy and combination studies in acute myeloid leukemia (AML) are substantially complete, with additional funding the Company plans to continue development of emavusertib in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene
Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948). For more information, visit Curis's website at www.curis.com.
Cautionary Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning Curis’s cash runway or expectations with respect to the timing or exercise of the January 2026 PIPE Financing Series B Warrants; Curis's expectations with respect to the dosing of the fifth patient in the TakeAim CLL study, and the therapeutic potential of emavusertib in combination with zanubrutinib to improve treatment outcomes, achieve complete remissions and/or undetectable MRD, and/or reduce time on treatment for patients with CLL; Curis's expectations with respect to enrollment of BTKi naïve and BTKi experienced populations in the TakeAim Lymphoma study; statements regarding updated PCNSL data and the timing of such data from the TakeAim Lymphoma study, or the use of such data to support regulatory filings for approval of emavusertib in PCNSL, and the therapeutic potential and tolerability of emavusertib in patients with PCNSL. Forward-looking statements may contain the words "believes," "expects," "anticipates," "plans," "intends," "seeks," "estimates," "assumes," "predicts," "projects," "targets," "will," "may," "would," "could," "should," "likelihood", "continue," "potential," "opportunity," "focus," "strategy," "mission," or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. Curis may experience adverse results, delays and/or failures in its drug development programs and may not be able to successfully advance the development of its drug candidates in the time frames it projects, if at all. Curis's drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed for commercialization. Favorable results seen in preclinical studies and early clinical trials of Curis's drug candidates may not be replicated in later trials. Curis is dependent on the success of emavusertib and any delays in the development of emavusertib could have a material adverse effect on its business. There can be no guarantee that the collaboration agreement with Aurigene or the CRADA with NCI will continue for their full terms, that Curis or its collaborators will each maintain the financial and other resources necessary to continue financing its portion of the research, development and commercialization costs, or that the parties will successfully discover, develop or commercialize drug candidates under the collaboration. Curis will require substantial additional capital to fund its business. Based on its available cash resources, it does not have sufficient cash on hand to support current operations within the next 12 months from the date of this press release. Curis will require substantial additional funding to fund the development of emavusertib through regulatory approval and commercialization, and to support its continued operations. If it is not able to obtain sufficient funding, it will be forced to delay, reduce in scope or eliminate the development of emavusertib, including related clinical trials and operating expenses, potentially delaying the time to market for, or preventing the marketing of, emavusertib, which could adversely affect its business prospects and its ability to continue operations, and would have a negative impact on its financial condition and its ability to pursue its business strategies. Curis faces substantial competition. Curis and its collaborators face the risk of potential adverse decisions made by the FDA, EMA and other regulatory authorities, investigational review boards, and publication review bodies. Curis may not obtain or maintain necessary patent protection and could become involved in expensive and time-consuming patent litigation and interference proceedings. Unstable market and economic conditions, natural disasters, public health crises, political crises and other events outside of Curis's control, including its ability to regain and maintain its listing on the Nasdaq Capital Market, could significantly disrupt its operations or the operations of third parties on which Curis depends and could adversely impact Curis's operating results and its ability to raise capital. Other important factors that may cause or contribute to actual results being materially different from those indicated by forward-looking statements include the factors set forth under the captions "Risk Factor Summary" and "Risk Factors" in our most recent Form 10-K, and the factors that are discussed in other filings that Curis periodically makes with the Securities and Exchange Commission. In addition, any forward-looking statements represent the views of Curis only as of today and should not be relied upon as representing Curis's views as of any subsequent date. Curis
disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by law.
For further information:
Investor Relations: IR@curis.com
CURIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(In thousands, except share and per share data)
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| Revenues, net | $ | 1,138 | $ | 3,345 | $ | 9,443 | $ | 10,908 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Cost of royalties | — | 17 | 45 | 98 | |||||||||||||||||||
| Research and development | 5,825 | 8,968 | 28,254 | 38,562 | |||||||||||||||||||
| General and administrative | 2,883 | 3,354 | 14,046 | 16,790 | |||||||||||||||||||
| Total operating expenses | 8,708 | 12,339 | 42,345 | 55,450 | |||||||||||||||||||
| Gain on release of liability related to sale of future royalties associated with sale of assets | 27,189 | — | 27,189 | — | |||||||||||||||||||
| Income (loss) from operations | 19,619 | (8,994) | (5,713) | (44,542) | |||||||||||||||||||
| Total other income (expense) | (263) | (624) | (1,869) | 1,153 | |||||||||||||||||||
| Net income (loss) | $ | 19,356 | $ | (9,618) | $ | (7,582) | $ | (43,389) | |||||||||||||||
| Net loss per common share (basic and diluted) | $ | 1.23 | $ | (1.25) | $ | (0.58) | $ | (6.88) | |||||||||||||||
| Weighted average common shares (basic and diluted) | 15,747,068 | 7,671,226 | 13,164,032 | 6,306,284 | |||||||||||||||||||
CURIS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands)
| December 31, 2025 | December 31, 2024 | |||||||||||||||||||||||||
| ASSETS | ||||||||||||||||||||||||||
Cash and cash equivalents | $ | 5,061 | $ | 19,997 | ||||||||||||||||||||||
| Restricted cash | 544 | 544 | ||||||||||||||||||||||||
| Accounts receivable | — | 3,349 | ||||||||||||||||||||||||
| Prepaid expenses and other assets | 3,427 | 4,999 | ||||||||||||||||||||||||
| Property and equipment, net | 62 | 231 | ||||||||||||||||||||||||
| Operating lease right-of-use asset | 1,890 | 3,163 | ||||||||||||||||||||||||
| Goodwill | 8,982 | 8,982 | ||||||||||||||||||||||||
| Total assets | $ | 19,966 | $ | 41,265 | ||||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||||||||||||||||||||
| Accounts payable and accrued liabilities | $ | 12,886 | $ | 10,135 | ||||||||||||||||||||||
| Operating lease liability | 1,618 | 2,954 | ||||||||||||||||||||||||
| Liability related to the sale of future royalties, net | — | 34,174 | ||||||||||||||||||||||||
| Total liabilities | $ | 14,504 | 47,263 | |||||||||||||||||||||||
| Total stockholders' equity (deficit) | 5,462 | (5,998) | ||||||||||||||||||||||||
| Total liabilities and stockholders' equity (deficit) | $ | 19,966 | $ | 41,265 | ||||||||||||||||||||||
FAQ
How did Curis (CRIS) perform financially in full-year 2025?
Curis significantly reduced its net loss in 2025 to $7.6 million, or $0.58 per share, from a $43.4 million loss in 2024. Lower operating expenses and a large non-cash gain from extinguishing a royalty-related liability drove the improvement, despite slightly lower revenues.
What drove Curis (CRIS) to report net income in Q4 2025?
Curis reported Q4 2025 net income of $19.4 million versus a $9.6 million loss a year earlier. The main driver was a non-cash $27.2 million gain from releasing the liability tied to future Erivedge royalties, following the sale of its Erivedge-related interests.
What is Curis’s cash position and funding outlook after 2025?
As of December 31, 2025, Curis held $5.1 million in cash and cash equivalents. Including $20.2 million PIPE proceeds received in January 2026 and potential Series B warrant exercises, management believes funding should support planned operations into the second half of 2027, subject to execution.
Why is the Erivedge transaction important for Curis (CRIS)?
Curis sold its Erivedge-related assets and License Agreement rights, receiving $2.5 million upfront and extinguishing a liability linked to future royalty sales, booking a $27.2 million non-cash gain. However, Curis will no longer receive Erivedge royalties, removing a prior revenue source.
What financial risks does Curis (CRIS) highlight in this update?
Curis states that, based on available cash resources, it lacks sufficient cash to support current operations within 12 months from the press release date. The company will require substantial additional funding to continue developing emavusertib and to maintain operations, creating notable financing risk.
How did Curis’s operating expenses change in 2025?
Research and development expenses fell to $28.3 million in 2025 from $38.6 million in 2024, mainly from lower employee, clinical, manufacturing and consulting costs. General and administrative expenses decreased to $14.0 million from $16.8 million, reflecting reduced employee-related and legal costs.
Filing Exhibits & Attachments
4 documents
Curis
NASDAQ:CRIS
CRIS Rankings
CRIS Latest News
CRIS Latest SEC Filings
Mar 24, 2026
[10-K] CURIS INC Files Annual Report
Mar 23, 2026
[Form 4] CURIS INC Insider Trading Activity
Mar 23, 2026
[Form 4] CURIS INC Insider Trading Activity
Mar 23, 2026
[Form 4] CURIS INC Insider Trading Activity
Mar 23, 2026
[Form 4] CURIS INC Insider Trading Activity
CRIS Stock Data
9.62M
12.79M
Biotechnology
Biological Products, (no Diagnostic Substances)
United States
LEXINGTON